The relation of putamen and caudate nucleus 18F-Dopa uptake to motor and cognitive performances in Parkinson's disease

Journal of the Neurological Sciences

Volumn 166, Issue 2, 1999, Pages 141-151

  Broussolle, E ^a,b,c   Dentresangle, C ^b,c   Landais, P ^b   Garcia Larrea, L ^b,c   Pollak, P ^d   Croisile, B ^e   Hibert, O ^e   Bonnefoi, F ^b   Galy, G ^b   Froment, J C ^a   Comar, D ^b  

^a Hop Neurologique Pierre W ^*  (France)

^b CERMEP IMAGERIE DU VIVANT   (France)

^c UNIVERSITÉ LYON 1   (France)

^d UNIV GRENOBLE ALPES   (France)

^e Laboratory of Neuropsychology   (France)

Author keywords

18F 6 fluoro L Dopa; Cognitive functions; Dopamine; Event related potentials; Motor disability; Parkinson's disease; Positron emission tomography (PET); Principal components analysis; Striatum

Indexed keywords

6 FLUORODOPA F 18; AMANTADINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; DECARBOXYLASE INHIBITOR; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; SELEGILINE;

ADULT; AGED; ARTICLE; CAUDATE NUCLEUS; CLINICAL ARTICLE; COGNITION; CONTROLLED STUDY; EVENT RELATED POTENTIAL; FEMALE; HUMAN; MALE; MOTOR PERFORMANCE; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PRINCIPAL COMPONENT ANALYSIS; PRIORITY JOURNAL; PUTAMEN;

ADULT; AFFECT; AGED; ANALYSIS OF VARIANCE; CASE-CONTROL STUDIES; CAUDATE NUCLEUS; COGNITION; DOPAMINE AGENTS; EVENT-RELATED POTENTIALS, P300; FEMALE; HUMANS; LEVODOPA; MALE; MIDDLE AGED; MOTOR SKILLS DISORDERS; PARKINSON DISEASE; PUTAMEN; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0032776109     PISSN: 0022510X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-510X(99)00127-6     Document Type: Article

References (67)

1. Agid Y., Ruberg M., Raisman R., Hirsch E., Javoy-Agid F. The biochemistry of Parkinson's disease. Stern G.M. Parkinson's disease. 1990;99-125 Chapman and Hall Medical, London.
2. 18F]fluoro-L-3,4-dihydroxyphenylalanine in the primate. J Neurochem. 48:1987;1077-1082.
3. Snow B.J., Tooyama I., McGeer E.G., Yamada T., Calne D.B., Takahashi H., et al. Human positron emission tomographic [18F]Fluorodopa studies correlate with dopamine cell counts and levels. Ann Neurol. 34:1993;324-330.
4. Brooks D.J., Salmon E.P., Mathias C.J., Quinn N., Leenders K.L., Bannister R., et al. The relationship between locomotor disability, autonomic dysfunction, and the integrity of the striatal dopaminergic system in patients with multiple system atrophy, pure autonomic failure, and Parkinson's disease, studied with PET. Brain. 113:1990;1539-1552.
5. Leenders K.L., Palmer A.J., Quinn N., Clark J.C., Firnau G., Garnett E.S., et al. Brain dopamine metabolism in patients with Parkinson's disease measured with positron emission tomography. J Neurol Neurosurg Psychiatry. 49:1986;853-860.
6. Vingerhoets F.J.G., Schulzer M., Calne D.B., Snow B.J. Which clinical sign of Parkinson's disease best reflects the nigrostriatal lesion? Ann Neurol. 41:1997;58-64.
7. Brooks D.J., Ibanez V., Sawle G.V., Quinn M.D., Lees A.J., Mathias C.J., et al. Differing patterns of striatal 18F-Dopa uptake in Parkinson's disease, multiple system atrophy and progressive supranuclear palsy. Ann Neurol. 28:1990;547-555.
8. Morrish P.K., Sawle G.V., Brooks D.J. Regional changes in [18F]dopa metabolism in the striatum in Parkinson's disease. Brain. 119:1996;2097-2103.
9. Brown R.G., Marsden C.D. Cognition in Parkinson's disease: from description to theory. Trends Neurosci. 13:1990;21-29.
10. Cooper J.A., Sagar H.J., Jordan N., Harvey N.S., Sullivan E.V. Cognitive impairment in early, untreated Parkinson's disease and its relationship to motor disability. Brain. 114:1991;2095-2122.
11. Dubois B., Pillon B. Cognitive deficits in Parkinson's disease. J Neurol. 244:1997;2-8.
12. Dubois B., Pillon B., Legault F., Agid Y., Lhermitte F. Slowing of cognitive processing in progressive supranuclear palsy. A comparison with Parkinson's disease. Arch Neurol. 45:1988;1194-1199.
13. Dubois B., Pillon B., Sternic N., Lhermitte F., Agid Y. Age-induced cognitive disturbances in Parkinson's disease. Neurology. 40:1990;38-41.
14. Gotham A.M., Brown R.G., Marsden C.D. Depression in Parkinson's disease: a quantitative and qualitative analysis. J Neurol Neurosurg Psychiatry. 49:1986;381-389.
15. Lees A.J., Smith E. Cognitive deficits in the early stages of Parkinson's disease. Brain. 106:1983;257-270.
16. Levin B.E., Llabre M.M., Weiner W.J. Cognitive impairments associated with early Parkinson's disease. Neurology. 39:1989;557-561.
17. Levin B.E., Tomer R., Rey G.J. Cognitive impairments in Parkinson's disease. Neurol Clin. 10:1992;471-485.
18. Owen A.M., James M., Leigh P.N., Summers B.A., Quinn N., Marsden C.D., et al. Fronto-striatal cognitive deficits at different stages of Parkinson's disease. Brain. 115:1993;1727-1751.
19. Taylor A.E., Saint-Cyr J.A., Lang A.E. Frontal lobe dysfunction in Parkinson's disease. Brain. 109:1986;845-883.
20. Alexander G.E., Crutcher M.D. Functional architecture of basal ganglia circuits: neural substrates of parallel processing. Trends Neurosci. 13:1990;266-271.
21. Brown R.G., Marsden C.D., Quinn N., Wyke M.A. Alterations in cognitive performance and affect arousal state during fluctuations in motor function in Parkinson's disease. J Neurol Neurosurg Psychiatry. 47:1984;454-465.
22. Stern Y., Langston W. Intellectual changes in patients with MPTP-induced parkinsonism. Neurology. 35:1985;1506-1509.
23. Pillon B., Dubois B., Cusimano G., Bonnet A.M., Lhermitte J., Agid Y. Does cognitive impairment in Parkinson's disease result from non-dopaminergic lesions? J Neurol Neurosurg Psychiatry. 52:1989;201-206.
24. Spicer K.B., Roberts R.J., LeWitt P.A. Neuropsychological performance in lateralized parkinsonism. Arch Neurol. 45:1988;429-432.
25. Tomer R., Levin B.E., Weiner W.J. Side of onset of motor symptoms influences cognition in Parkinson's disease. Ann Neurol. 34:1993;579-584.
26. Garcia-Larrea L., Broussolle E., Gravejat M.F., Chazot G., Mauguière F. Brain responses to detection of right or left somatic targets are symmetrical in unilateral Parkinson's disease. A case against the concept of 'parkinsonian neglect'. Cortex. 32:1996;679-691.
27. Tachibana H., Aragane K., Kawabata K., Sugita M. P3 latency change in aging and Parkinson's disease. Arch Neurol. 54:1997;296-302.
28. Girotti F., Carella F., Grassi M.P., Soliveri P., Marano R., Caraceni T. Motor and cognitive performances of Parkinsonian patients in the 'on' and 'off' phases of the disease. J Neurol Neurosurg Psychiatry. 49:1986;657-660.
29. Gotham A.M., Brown R.G., Marsden C.D. 'Frontal' cognitive function in patients with Parkinson's disease 'on' and 'off' levodopa. Brain. 111:1988;299-321.
30. Malapani C., Pillon B., Dubois B., Agid Y. Impaired simultaneous cognitive task performance in Parkinson's disease: a dopamine-related dysfunction. Neurology. 44:1994;319-326.
31. Pillon B., Dubois B., Bonnet A.M., Esteguy M., Guimaraes J., Vigouret J.M., et al. Cognitive 'slowing' in Parkinson's disease fails to respond to levodopa treatment: the 'fifteen objects test'. Neurology. 39:1989;762-768.
32. Prasher D., Findley L. Dopaminergic induced changes in cognitive and motor processing in Parkinson's disease: an electrophysiological investigation. J Neurol Neurosurg Psychiatry. 54:1991;603-609.
33. Rafal R.D., Posner M.I., Walker J.A., Friedrich F.J. Cognition and the basal ganglia. Separating mental and motor components of performance in Parkinson's disease. Brain. 107:1984;1083-1094.
34. Stanzione P., Fattaposta F., Giunti P., D'Alessio C., Tagliati M., Africano C., et al. P300 variations in parkinsonian patients before and during dopaminergic monotherapy: a suggested dopamine component in P300. Electroencephalogr Clin Neurophysiol. 80:1991;446-453.
35. Dubois B., Pillon B., Lhermitte F., Agid Y. Cholinergic deficiency and frontal dysfunction in Parkinson's disease. Ann Neurol. 28:1990;117-121.
36. Holthoff-Detto V.A., Kessler J., Herholz K., Bönner H., Pietrzyk U., Würker M., et al. Functional effects of striatal dysfunction in Parkinson's disease. Arch Neurol. 54:1997;145-150.
37. Acton P.D., Pilowsky L.S., Suckling J., Brammer M.J., Ell P.J. Registration of dynamic dopamine D2 receptor images using principal component analysis. Eur J Nucl Med. 24:1997;1405-1412.
38. Boles D.B. Factor analysis and the cerebral hemispheres: 'unlocalized' functions. Neuropsychologia. 34:1996;723-736.
39. Chapman R.M., McCrary J.W. EP component identification and measurement by principal components analysis. Brain Cogn. 27:1995;288-310.
40. Eidelberg D., Moeller J.R., Dhawan V., Spetsieris P., Takikawa S., Ishikawa T., et al. The metabolic topography of parkinsonism. J Cereb Blood Flow Metab. 14:1994;783-801.
41. Gibb W.R.G., Lees A.J. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry. 51:1988;745-752.
42. Fahn S., Elton R.L. Unified Parkinson's disease rating scale. Fahn S., Marsden C.D., Calne D., Goldstein M. Recent developments in Parkinson's disease. 1987;153-163 Macmillan Healthcare Information, Floral Park, NJ.
43. Langston J.W., Widner H., Goetz C.G., Brooks D., Fahn S., Freeman T., et al. Core assessment program for intracerebral transplantations (CAPIT). Mov Disord. 7:1992;2-13.
44. Coblentz J.M., Mattis S., Zingesser L.H., Kassof S.S., Wisniewski H.M., Katzman R. Presenile dementia. Clinical aspects and evaluation of cerebrospinal fluid dynamics. Arch Neurol. 29:1973;299-308.
45. El-Awar M., Becker J.T., Hammond K.M., Nebes R.D., Boller F. Learning deficit in Parkinson's disease. Comparison with Alzheimer's disease and normal aging. Arch Neurol. 44:1987;180-184.
46. Schmidt R., Freidl W., Fazekas F., Reinhart B., Grieshofer P., Koch M., et al. The Mattis Dementia Rating Scale: normative data from 1001 healthy volunteers. Neurology. 44:1994;964-966.
47. Von Frenckell R., Sanchez-Blanque A., Bobon D.P. Reparametrisation of the Beck-Pichot Depression Inventory. A contribution to optimal scaling. J Psy Biol Ther. 1:1981;34-37.
48. Cardebat D., Doyon B., Puel M., Goulet P., Joanette Y. Evocation lexicale formelle et sémantique chez des sujets normaux. Performances et dynamiques de production en fonction du sexe, de l'âge et du niveau d'étude. Acta Neurol Belg. 90:1990;207-217.
49. Grober E., Buschke H., Crystal H., Bang S., Dresner R. Screening for dementia by memory testing. Neurology. 38:1988;900-903.
50. Calicis F., Wyns C., Van der Linden M. Epreuve de rappel indicé. Manuel d'utilisation. Adaptation en français d'une épreuve de Grober et Buschke. 1995;Faculté de Psychologie U.C.L, Louvain-la-Neuve.
51. Picton T.W. The P3 wave of the human event-related potential. J Clin Neurophysiol. 9:1992;456-479.
52. Kutas M., McCarthy G., Donchin E. Augmenting mental chronometry: the P3 as a measure of stimulus evaluation time. Science. 197:1977;792-795.
53. Magliero A., Bashore T.R., Coles M.G.H., Donchin E. On the dependence of P3 latency on stimulus evaluation processes. Psychophysiology. 21:1984;171-186.
54. Garcia-Larrea L., Bastuji H., Mauguière F. Unmasking of cortical SEP components by change in stimulus rate. A topographic study. Electroencephalogr Clin Neurophysiol. 84:1992;71-83.
55. 18F)Fluoro-L-Dopa via two chiral auxiliaries. J Appl Radiat Isot. 44:1993;737-744.
56. Mazoyer B., Trebossen C., Schoukroun C., Verrey B., Syrota A., Vacher J., et al. Physical characteristics of TTV03, a new high spatial resolution time-of-flight positron tomograph. IEEE Trans Nucl Sci. 37:1990;778-782.
57. Patlak C.S., Blasberg R.G. Graphical evaluation of blood to brain transfer constants from multiple time uptake data. Generalizations. J Cereb Blood Flow Metab. 5:1985;584-590.
58. Takikawa S., Dhawan V., Chaly T., Robeson W., Dahl R., Zanzi I., et al. Input functions for 6-[Fluorine-18]Fluorodopa quantitation in Parkinsonism: comparative studies and clinical correlations. J Nucl Med. 35:1994;955-963.
59. Lee C.S., Schulzer M., Mak E.K., Snow B.J., Tsui J.K., Calne S., et al. Clinical observations on the rate of progression of idiopathic parkinsonism. Brain. 117:1994;501-507.
60. Morrish P.K., Sawle G.V., Brooks D.J. Clinical and (18F)dopa PET findings in early Parkinson's disease. J Neurol Neurosurg Psychiatry. 59:1995;597-600.
61. Morrish P.K., Sawle G.V., Brooks D.J. An [18F]dopa-PET and clinical study of the rate of progression in Parkinson's disease. Brain. 119:1996;585-591.
62. Eidelberg D., Moeller J.R., Dhawan V., Sidtis J.J., Ginos J.Z., Strother S.C., et al. The metabolic anatomy of Parkinson's disease: complementary [18F]fluorodeoxyglucose and [18F]fluorodopa positron emission tomographic studies. Mov Disord. 5:1990;203-213.
63. Hansch E.C., Syndulko K., Cohen S.N., Goldberg Z.I., Potvin A., Tourtellotte W.W. Cognition and Parkinson's disease: an event related perspective. Ann Neurol. 11:1982;599-607.
64. Ruzicka E., El Massioui M. Event-related potentials in Parkinson's disease: a review. Behav Neurol. 6:1993;15-26.
65. Bodis-Wollner I., Borod J.C., Cicero B., Haywood C.S., Raskin S., Mylin L., et al. Modality dependent changes in event-related potentials correlate with specific cognitive functions in non-demented patients with Parkinson's disease. J Neural Transm Par Dis Dement Sect. 9:1995;197-209.
66. Rumbach L., Tranchant C., Viel J.F., Warter J.M. Event-related potentials in Parkinson's disease: a 12-month follow-up study. J Neurol Sci. 116:1993;148-151.
67. Bonnet A.-M., Loria Y., Saint-Hilaire M.-H., Lhermitte F., Agid Y. Does long-term aggravation of Parkinson's disease result from non-dopaminergic lesions? Neurology. 37:1987;1539-1542.